NCT Number: NCT02191163
Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency
Study to determine the efficacy and safety of Antistax® film coated tablets in improving microcirculation of the skin in the leg of patients with chronic venous insufficiency (CVI)
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female
- >= 18 years of age
- CVI I or CVI II (without expanded trophic disturbances)
- Willing and able to give written informed consent in accordance to Good Clinical Practice and local legislation prior to participation in the study
Exclusion criteria
Concomitant disease(s) exclusion criteria:
- Decompensated cardiac insufficiency
- Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
- Peripheral arterial disease (ankle/arm pressure index < 0.9)
- Current acute phlebitis or thrombosis
- Renal insufficiency (Serum creatinine > 1.5 mg/dl)
- Liver disease (SGPT (ALAT) > 3x upper limit of normal)
- Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
- Anamnestic indications of diabetic microangiopathy or polyneuropathy
- Drug and/or alcohol abuse
- Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- Severe climacteric complaints or changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- Immobility
- Avalvulie
- Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- State after pulmonary embolism
- Recognized hypersensitivity to the trial drug ingredients
- Current florid venous ulcus
- Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
Previous treatment(s) exclusion criteria:
- Treatment with venous drugs within the last 4 weeks
- Changes in, or initiation with, treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
Concomitant treatment/non-drug therapy exclusion criteria:
- Other venous drugs apart from the trial medication
- Compression bandages
- Venous surgery of the leg used for the fluxmetry
- Extensive use (i.e. on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
- Major surgery requiring full anesthesia
Other exclusion criteria:
- Previously studied under this protocol
- Participation in another clinical trial within the previous 90 days or during the present study
- Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- Patients in a bad general health state according to the investigator's judgment
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Changes from baseline in the resting flux
Time frame: Baseline, after 6 weeks of treatment
measured in the frequency range 10-37 kHz on the skin of the inside lower leg using the Laser Doppler Fluxmetry
Secondary outcomes
-
Changes from baseline in the resting flux
Time frame: Baseline, after 3 weeks of treatment
measured in the frequency range 10-37 kHz
-
Changes in the resting flux
Time frame: Baseline, after 3 and 6 weeks of treatment
measured in the frequency range <10 kHz
-
Changes in the combined resting fluxes (<37 kHz)
Time frame: Baseline, after 3 and 6 weeks of treatment
-
Changes in the transcutaneous oximetry (TcPO2)
Time frame: Baseline, after 3 and 6 weeks of treatment
measured on the inside lower leg of the more CVI-affected leg
-
Change from baseline in the calf circumference of the most affected leg
Time frame: Baseline, after 3 and 6 weeks of treatment
-
Change from baseline in the ankle circumference of the most affected leg
Time frame: Baseline, after 3 and 6 weeks of treatment
-
Change from baseline in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
Time frame: Baseline, after 3 and 6 weeks of treatment
-
Global efficacy assessment by patient on a 4-point verbal rating scale (VRS)
Time frame: after 6 weeks of treatment
-
Global efficacy assessment by investigator on a 4-point VRS
Time frame: after 6 weeks of treatment
-
Number of patients with adverse events
Time frame: up to 16 weeks
-
Number of patients with clinically relevant changes in laboratory values
Time frame: Baseline, up to 16 weeks
-
Number of patients with clinically significant changes in vital signs
Time frame: Baseline, up to 16 weeks
-
Global tolerability assessment by investigator on a 4-point VRS
Time frame: after 6 weeks of treatment
-
Global tolerability assessment by patient on a 4-point VRS
Time frame: after 6 weeks of treatment
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency
Important dates
- Study start
- 2002
- Primary completion
- 2002
- First posted
- Jul 16, 2014
- Registry last updated
- Jul 16, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Isolated Great Saphenous Vein Stripping for Treatment of Varicose Veins in Lower Limbs
NCT07616115
Cardiovascular Diseases, Saphenous Vein
São Paulo, Brazil
View Trial DetailsDigital Supported Compression Bandaging in Patients With Chronic Edema in the Lower Limbs
NCT06438133
Cardiovascular Diseases, Compression; Vein
Bispebjerg, Capital Region, Denmark
View Trial DetailsTransient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)
NCT02061254
Cardiovascular Diseases, Fibrosis
Tours, France
View Trial DetailsThe Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency
NCT01558024
Cardiovascular Diseases, Vascular Diseases
Montpellier, France
View Trial Details